aTYR PHARMA INC (ATYR)

Current Report Filed: 2026-05-15

Key Insights

aTyr Pharma announced Q1 2026 financial results on May 15, 2026, with the full details contained in the press release (Exhibit 99.1) which is not included in this 8-K filing summary.
The company is trading on the Nasdaq Capital Market under ticker ATYR and maintains its Delaware incorporation with headquarters in San Diego, California.
As a non-emerging growth company, aTyr Pharma is subject to full SEC compliance requirements and cannot utilize extended transition periods for new accounting standards.

Quarterly Report Filed: 2026-05-15

Key Insights

Filing contains extensive XML markup references but minimal substantive financial data, making it difficult to assess actual Q1 2026 operational performance or material changes in revenue, expenses, or cash position.
Multiple references to fair value measurements, investment holdings (municipal bonds, corporate debt securities, commercial paper), and short-term investments indicate the company is actively managing its balance sheet and liquidity position.
Recent subsequent events noted (May 1 and May 12, 2026) related to Kyorin Pharmaceutical collaboration and development/regulatory milestones suggest ongoing progress in pipeline partnerships, though specific financial impacts are not detailed in this filing excerpt.
Significant equity compensation activity evidenced across multiple stock plans (2015 Stock Plan, 2022 Inducement Plan, Employee Stock Purchase Plan) with RSU and option references, indicating potential shareholder dilution considerations.

Insider Trading Filed: 2026-05-13

Key Insights

Director Paul Schimmel received a grant of 50,000 stock options at $0.95 exercise price on 05/11/2026, vesting in full by May 2027, representing standard non-employee director compensation with no immediate stock acquisition.
The option grant at $0.95 per share is relatively modest in value and represents routine equity compensation rather than significant insider confidence in future stock price appreciation.
No non-derivative securities were acquired or disposed of in this transaction, indicating this is purely a compensation grant rather than open market buying activity that might signal insider bullishness.

Insider Trading Filed: 2026-05-13

Key Insights

Director Timothy Coughlin received a grant of 50,000 stock options with a strike price of $0.95, exercisable for 10 years, indicating the company's current stock valuation is at or near this level.
The options vest on the earlier of May 11, 2027 or the 2027 Annual Shareholder Meeting, which is a standard non-employee director compensation arrangement with typical one-year vesting.
This is a routine equity compensation grant to a board member under the company's non-employee director compensation policy, not an insider purchase or sale that would signal confidence or concern about stock valuation.

Insider Trading Filed: 2026-05-13

Key Insights

Director Sara Zaknoen received a grant of 50,000 stock options with an exercise price of $0.95, vesting in full by May 11, 2027 or at the 2027 Annual Meeting, indicating the company is using equity compensation to retain board members.
The low exercise price of $0.95 per share suggests the stock was trading near or below this level at the time of grant (May 11, 2026), which may indicate weak stock performance or a down round valuation for the company.
This is a routine non-employee director compensation action under the company's standard equity plan, representing a typical board retention practice rather than a signal of insider confidence or significant business developments.

Insider Trading Filed: 2026-05-13

Key Insights

Director Lucas Svetlana received a grant of 50,000 stock options at an exercise price of $0.95, vesting on the earlier of May 11, 2027 or the 2027 Annual Meeting, reflecting standard non-employee director compensation.
The option grant represents routine equity compensation under aTYR's director compensation policy rather than evidence of insider conviction about stock value, as this is a scheduled award tied to board service.
No actual common stock purchases were made in this transaction, indicating no meaningful insider buying at current market prices despite the director's participation in the company's governance.

Insider Trading Filed: 2026-05-13

Key Insights

Director Jane A Gross received a grant of 50,000 stock options with a strike price of $0.95, vesting on the earlier of May 11, 2027 or the 2027 Annual Shareholder Meeting, representing standard non-employee director compensation.
The option strike price of $0.95 is notably low, suggesting the stock was trading near this level on the grant date (05/11/2026), which may indicate depressed valuation or financial challenges for the company.
This is a routine equity grant to a board member under the company's standard non-employee director compensation policy, with no significant insider buying or selling activity that would indicate insider confidence or concern.

Insider Trading Filed: 2026-05-13

Key Insights

Director Eric Benevich received a grant of 50,000 stock options with an exercise price of $0.95, vesting in full by May 11, 2027 or at the 2027 Annual Meeting, indicating standard non-employee director compensation.
The option grant represents routine equity compensation under aTYR's director compensation policy rather than a discretionary insider purchase, suggesting no material conviction signal about company valuation.
No actual securities were acquired or disposed of in this transaction—only derivative options were granted—limiting this filing's significance as an insider trading signal.

Current Report Filed: 2026-05-11

Key Insights

aTyr has $68.3 million in cash and equivalents as of March 31, 2026, providing a substantial runway for continued development of efzofitimod in pulmonary sarcoidosis.
The FDA's feedback resulted in a redesigned Phase 3 trial using FVC as primary endpoint and KSQ-Lung as secondary endpoint, with increased dosing frequency from once every 4 weeks to once every 3 weeks, representing a meaningful pivot from the prior EFZO-FIT study design.
The new Phase 3 trial will enroll up to 372 patients with restrictive lung disease (FVC ≤80% predicted), focused on a narrower patient population based on positive signals from the prior trial showing a 124 ml FVC difference in this subgroup.
Enhanced safety monitoring including anti-synthetase syndrome surveillance and a data safety monitoring committee reflects regulatory concerns that must be addressed, with IND submission planned for June 2026.

Current Report Filed: 2026-03-05

Key Insights

aTyr Pharma reported its full-year 2025 financial results, providing investors with an update on the company's operational and financial performance.
The company did not provide any forward-looking guidance or commentary on future product development or regulatory milestones, which could be a concern for investors looking for visibility into the company's pipeline and growth prospects.
The lack of any major business updates or news in this 8-K filing suggests the company may be in a relatively stable, ongoing operational phase without significant near-term catalysts.

Annual Report Filed: 2026-03-05

Key Insights

aTYR PHARMA INC reported a significant increase in license and collaboration revenues in 2025, likely driven by its partnership with Kyorin Pharmaceutical Co Ltd.
The company's balance sheet remains strong, with a substantial amount of short-term investments and commercial paper holdings as of the end of 2025.
aTYR PHARMA continues to invest heavily in research and development, with R&D expenses increasing year-over-year, which may impact the company's profitability in the near term.

Insider Trading Filed: 2026-01-09

Key Insights

The reporting person, Nancy Denyes, acquired 31,555 shares of aTYR PHARMA INC (ATYR) common stock through the company's 2015 Employee Purchase Plan in multiple transactions.
Denyes was granted a stock option to purchase 412,500 shares of ATYR common stock at an exercise price of $0.7127 per share, which will vest in 36 equal monthly installments starting February 9, 2026.
The stock option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer, providing an incentive for Denyes to remain with the company during a potential acquisition.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information